These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25867595)

  • 1. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.
    Iacono P; Battaglia Parodi M; Bandello F
    Am J Ophthalmol; 2015 May; 159(5):996-7. PubMed ID: 25867595
    [No Abstract]   [Full Text] [Related]  

  • 2. Short-Term Changes in Choroidal Thickness After Aflibercept Therapy for Neovascular Age-Related Macular Degeneration.
    Kim JH
    Am J Ophthalmol; 2015 Jul; 160(1):207. PubMed ID: 26054473
    [No Abstract]   [Full Text] [Related]  

  • 3. Aflibercept anti-vascular endothelial growth factor therapy in vitrectomized eyes with neovascular age-related macular degeneration.
    Jung JJ; Hoang QV; Arain MZ; Chang S
    Acta Ophthalmol; 2016 May; 94(3):e249-50. PubMed ID: 26401896
    [No Abstract]   [Full Text] [Related]  

  • 4. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Schachat AP
    Am J Ophthalmol; 2013 Jul; 156(1):1-2.e1. PubMed ID: 23791369
    [No Abstract]   [Full Text] [Related]  

  • 5. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.
    Arcinue CA; Ma F; Barteselli G; Sharpsten L; Gomez ML; Freeman WR
    Am J Ophthalmol; 2015 Mar; 159(3):426-36.e2. PubMed ID: 25461263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.
    Muftuoglu IK; Arcinue CA; Tsai FF; Alam M; Gaber R; Camacho N; You Q; Freeman WR
    Am J Ophthalmol; 2016 Jul; 167():1-9. PubMed ID: 27049000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration.
    Yonekawa Y; Andreoli C; Miller JB; Loewenstein JI; Sobrin L; Eliott D; Vavvas DG; Miller JW; Kim IK
    Am J Ophthalmol; 2013 Jul; 156(1):29-35.e2. PubMed ID: 23668679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. THE INFLUENCE OF VITREOMACULAR ADHESION ON OUTCOMES AFTER AFLIBERCEPT THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    McKibbin MA; Suter CA; Willis TA
    Retina; 2015 Oct; 35(10):1951-6. PubMed ID: 25932561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Initial experience with aflibercept in the management of patients with wet age-related macular degeneration refractory to ranibizumab and/or bevacizumab].
    Cervera RE; Castro V; Montero J; Torralba C; Gracia A
    Arch Soc Esp Oftalmol; 2014 Jan; 89(1):42-3. PubMed ID: 24269436
    [No Abstract]   [Full Text] [Related]  

  • 10. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
    Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
    Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply: To PMID 25461263.
    Arcinue CA; Ma F; Barteselli G; Sharpsten L; Gomez ML; Freeman WR
    Am J Ophthalmol; 2015 May; 159(5):997. PubMed ID: 25867596
    [No Abstract]   [Full Text] [Related]  

  • 13. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT.
    Mantel I; Gianniou C; Dirani A
    Retina; 2016 Jan; 36(1):53-8. PubMed ID: 26166797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration.
    He L; Silva RA; Ayoub N; Moshfeghi DM; Leng T
    Ophthalmic Surg Lasers Imaging Retina; 2015 May; 46(5):542-9. PubMed ID: 26057757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
    de Massougnes S; Dirani A; Mantel I
    Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reply: To PMID 25555799.
    Koizumi H; Yamamoto A; Maruko I; Okada AA; Iida T; Kano M; Saito M; Sekiryu T; Kawasaki R
    Am J Ophthalmol; 2015 Jul; 160(1):207-8. PubMed ID: 26054474
    [No Abstract]   [Full Text] [Related]  

  • 20. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
    Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
    Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.